The specific inactive ingredients used depend on the dosage form (ointment, area, or lotion) and help the product retain its chemical and physical integrity while increasing the shelf-life.

[5][10] While most side effects are mild, a medical professional should be contacted if severe rash, acne, skin deterioration, excessive hair growth, or abnormal weight gain occur.

Gene expression is subsequently modified to produce anti-inflammatory mediators while preventing the formation of inflammatory agents thus reducing overall inflammation and immune system response.

Ongoing research predicts that Amcinonide prevents the release of arachidonic acid which, in turn, stops the synthesis of the inflammation mediators prostaglandins and leukotrienes.

Due to Amcinonide's high affinity for the glucocorticoid receptor, a neuroactive ligand-receptor interaction occurs and the initial acid release is inhibited, thus helping to alleviate any itching/ burning symptoms.

[15] Lederle Laboratories, most famous for the discovery of the antibacterial tetracycline drug class, began to manufacture of Amcinonide before being acquired by Cyanamid.

Specifically, in one acceptability study conducted on a weekly basis, one-fifth of patients using both placebo and Cyclocort 0.1% lotion reported various discomforts at multiple interviews.

Specifically, 0.1% strength preparations of each compound were tested against 0.025% Synalar Gel and 0.1% Betnovate Cream using a vasoconstrictor assay to determine bioavailability and anti-inflammatory effects.

All formulations had similar bioavailability profiles with the peak of the curve coming approximately 12 hours after topical administration and covering with an occlusive dressing.

It was found that treatment of dermatitis with Amcinonide achieved significant improvement over the one-week trial period, thus demonstrating adequate efficacy in treating psoriasis, eczema, and even parapsoriasis.

Three equal strength formulations of Amcinonide were prepared (cream, combination-ointment, combination-cream) were compared against similar corticosteroids already on the market in the United Kingdom (Betnovate, Metosyn, Synalar, Temetex, Dermovate, and Halciderm).

It was found that 0.1% Amcinonide cream was significantly more bio-active than other 'potent' classified drugs and was subsequently assigned to the 'very potent' category, as established by the UK MIMS potency classification system.

[21] In a study conducted by Fedler, Pilz, & Frosch, 1993, the long term usage of Amcinonide, along with other topical corticosteroids, was tested on women with a history of dermatitis who had otherwise been relatively healthy.

[26][27] More recently, however, the drug formulation itself has not been patented but ways to incorporate it into occlusive dressings such as a pressure sensitive adhesive layer as demonstrated by Senju USA, Inc. in 2012 - 2014.